Clinical Trial

The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 14, 2022 (before its estimated December 31, 2023 completion). Its status may not reflect the trial's current state.
Summary
To study the safety and effectiveness of CAR-T Cell therapy on HIV patients whose plasma HIV has been successfully suppressed after cART, which is expected to enhance the res-constitution of HIV-specific immune function to assist the eradication of HIV reservoir.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2017-08-02; most recent amendment 2022-09-13.
Status change: Not Yet Recruiting → Recruiting 2018-04-22
Trial Details
NCT Number NCT03240328
Lead Sponsor Guangzhou 8th People's Hospital
Collaborators: Sun Yat-sen University
Conditions HIV/AIDS
Enrollment 40 participants
Start Date 2017-10-04
Primary Completion 2023-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2022-09-14